


1fn

Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**

Applicant : Hatake, et al.  
App. No : 10/564,302  
Filed : January 10, 2006  
For : DRUG FOR CANCER THERAPY  
Examiner : Unknown  
Art Unit : Unknown

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 16, 2006

(Date)

*Che S. Chereskin*

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing and enclosing 15 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

*Che S. Chereskin*


Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404



## INFORMATION DISCLOSURE STATEMENT

Applicant : Hatake, et al.  
App. No : 10/564,302  
Filed : January 10, 2006  
For : DRUG FOR CANCER THERAPY  
Examiner : Unknown  
Art Unit : Unknown

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 15 references to be considered by the Examiner. These 15 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement are enclosed.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Feb. 16, 2006

By: Che S. Chereskin

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/564,302
Filing Date	January 10, 2006
First Named Inventor	Hatake, et al.
Art Unit	Unknown
Examiner	Unknown
Attorney Docket No.	TOYA108.010APC

(Multiple sheets used when necessary)

SHEET 1 OF 2

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
		WO 98/33509	08/06/98	Pharming B.V.		
		WO 00/12541	03/09/00	Rebecca Gardner		
		WO 00/12542	03/09/00	Rebecca Gardner		
		JP 07-309771	11/28/95	Morinaga Milk Ind Co Ltd		Abstract
		JP 08-073499	03/19/96	Snow Brand Milk Prod Co Ltd		Abstract
		JP 10-059864	03/03/98	Morinaga Milk Ind Co Ltr		Abstract

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
		Eliassen, et al. "Enhanced Antitumour Activity of 15-Residue Bovine Lactoferricin Derivatives Containing Bulky Aromatic Amino Acids and Lipophilic N-Terminal Modifications," <i>Journal of Peptide Science</i> , Vol. 9, pp. 510-517, 2003.	
		Eliassen, et al. "Evidence for a Direct Antitumor Mechanism of Action of Bovine Lactoferricin," <i>Anticancer Research</i> , Vol. 22, pp. 2703-2710, 2002.	
		Iigo, et al. "Inhibitory Effects of Bovine Lactoferrin on Colon Carcinoma 26 Lung Metastasis in Mice," <i>Clinical &amp; Experimental Metastasis</i> , Vol. 17, pp. 35-40, 1999.	
		Sakurai, et al. "Rituximab ni yoru Hotai Isonsei no Saibo Shogai Sayo (CDC) ni Oyobosu Lactoferrin Bunkaibutsu (LFH) no Tenka Koka," <i>Rinsho Ketsueki</i> (30 August, 2004 (30.08.04), Vol. 45, No. 8, page 915, PS-2-186 with English translation	√
		Sakurai, et al. "Lactoferrin Bunkaibutsu (LFH) no Rituximab ni yoru Hotai Isonsei no Saibu Shogai Sayo (CDC) ni Oyobosu Tenka Koka," Vol. 63 <sup>rd</sup> , page 308, P-0799 with English translation	√
		Yoo, et al. "Bovine Lactoferrin and Lactoferricin, a Peptide Derived from Bovine Lactoferrin, Inhibit Tumor Metastasis in Mice," <i>Japanese Journal of Cancer Research</i> , Vol. 88, pp. 184-190, February 1997.	
		Yoo, et al. "Apoptosis in Human Leukemic Cells Induced by Lactoferricin, a Bovine Milk Protein-Derived Peptide: Involvement of Reactive Oxygen Species," <i>Biochemical and Biophysical Research Communications</i> , Vol. 237, pp. 624-628, 1997.	
		Yoo, et al. "Bovine Lactoferrin and Lactoferricin™ Inhibit Tumor Metastasis in Mice," <i>Adv. Exp. Med. Biol.</i> , Vol. 443, pp. 285-291, 1998.	
		International Search Report dated June 22, 2005.	

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/564,302
	Filing Date	January 10, 2006
	First Named Inventor	Hatake, et al.
	Art Unit	Unknown
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 2 OF 2	Attorney Docket No.	TOYA108.010APC

2382278  
021606

Examiner Signature	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.